Puberty Suppression and Cardiometabolic Health
Recruiting
Observational Study
Transgenderism
Insulin Sensitivity/Resistance
Endothelial Dysfunction
Vascular Stiffness
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 9 – 14
- Sex
- Male
- Study type
- Observational
- Participants needed
- 30 (estimated)
- Sponsor
- University of Colorado, Denver · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This observational study will evaluate the effect of puberty suppression on insulin sensitivity, metabolic rate and vascular health among transgender female youth at baseline and 6 months after initiation of a gondoatropin releasing hormone agonist compared to matched cisgender male controls.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Identify as a transgender female or cisgender male
* Age 9-14 years at the time of enrollment
* Tanner Stage 2-3 baseline pubertal development
* Plan to start gonadotropin releasing hormone analogue clinically in \< 2 months (for transgender females only)
Exclusion Criteria:
…
Contacts